Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

GNBT, CBIS, WPNV - Stock Alerts! from CRWEfinance.com - Generex Biotechnology, Cannabis Science, WindPower Innovations

crwefinancelogo2

 

signup3m

 

 

___

  Cannabis Science, Inc. (OTCPK:CBIS)

CBIS, a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased with its progress with RockBrook Inc. as CBIS's first commercialization license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on CBIS formulations, and delivery systems for the CBIS Brand of Pharmaceutical Products and CBIS Ailment Formulations within the State of Colorado.

On August 30, 2010, FOX affiliate KTXL ("FOX40") aired one of the first paid U.S. television ads for a Cannabis Dispensary called CannaCare on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials. Similarly, Cannabis Science is acquiring public testimonials using data acquired from RockBrook patients who use Cannabis Science Brands to evaluate our medical marijuana products prior to FDA clinical trials.

CBIS engages in the research and development, production, and commercialization of phytocannabinoid based pharmaceutical products. CBIS's cannabinoid pharmaceuticals targets various serious needs that include neuro-muscular disorders; neuropathic pain related to spinal cord injuries, as well as conditions, such as AIDS/HIV; chronic pain; respiratory inflammation related to both infections, such as influenza and to autoimmune diseases comprising asthma; cancer, including pain management, and control of cancer in conditions, such as pheochromocytoma; digestive illnesses consisting of gastroesophageal reflux disease, crohnâs disease, and irritable bowel syndrome; dermatological infections, such as flesh eating disease; and sleep disorders. CBIS offers its products under various product categories, including non-prescription drugs, nutraceuticals, psychoactive medications, and non-psychoactive medications. CBIS is based in San Francisco, California.

To learn more about CBIS visit: http://www.cannabisscience.com

*********************

 WINDPOWER INNOVATIONS, INC. (WPNV.PK)

WPNV, a wind power infrastructure and smart grid solutions company, announced earlier this week the availability of a recent interview with Chief Technical Officer Ian K. Griffiths conducted by Virmmac.com, a virtual IR, marketing, media, and administration center focused on providing companies ongoing support, and Stocktalk101.com, designed to educate traders and investors alike in OTC and Pink sheet companies.

Mr. Griffiths will discuss in detail the unique nature of WPNV and how it sees its role in the evolution of wind energy.

WPNV remanufactures and repairs wind turbine gear boxes and blades in the United States. WPNV also refurbishes the entire turbine, including tower, blades, and spare parts. WPNV is based in Queen Creek, Arizona.

To learn more about WPNV visit: http://www.windpowerinnovationsinc.com

*********************

  Generex Biotechnology Corporation (Nasdaq:GNBT)

GNBT, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, this week announced that it has entered into a long-term marketing and distribution agreement with Merck,  S.A. de C.V. in Mexico for the distribution  of one of GNBT's proprietary over-the-counter products, Glucose RapidSpray brand formulated glucose spray product.  Merck will market and distribute the product in Mexico as Diabion GlucoShot.

GNBT, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. GNBT develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. GNBT's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. GNBT's under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. GNBT markets its products through distributors and retail chains in Ecuador, Canada, and the United States. GNBT has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum. GNBT was founded in 1983 and is based in Toronto, Canada.

To learn more about GNBT visit: http://www.generex.com

___

********************************************************************

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars from a third party (VNC Associates LLC) for one (1) day of advertising for CANNABIS SCIENCE INC (OTC BB: CBIS.OB)